T2S Group Holding Makes History with IPO on Casablanca Stock Exchange
In a monumental move for the Moroccan capital markets, T2S Group Holding, a leading medical technology firm, has officially begun trading on the Casablanca Stock Exchange. This marks a significant milestone as it is the first listing of 2026, following a successful initial public offering (IPO) that raised an impressive MAD 1.1 billion (approximately $120 million). The IPO was structured to include a MAD 350 million capital increase, alongside a MAD 750 million share sale executed by Trone Investment Holdings, an investment vehicle associated with Helios Investment Partners. With shares priced at MAD 223 each, T2S’s market valuation post-listing stands at around MAD 4.9 billion.
The offering saw a remarkable response from investors, attracting over 111,000 subscribers and generating demand that soared to MAD 48.1 billion, making it nearly 44 times oversubscribed. Specifically, investors requested a staggering 215.8 million shares against the mere 4.93 million shares available, leading to an average allocation rate of just 2.29%. Founded in 1992 by Abderraouf Sordo, T2S has established itself as the largest integrated medical technology company in Morocco, supplying and maintaining medical equipment across more than 20 African countries. The company has also ventured into radiopharmaceutical production and hospital software development, forming strategic partnerships with industry leaders like GE HealthCare, BioMérieux, Boston Scientific, and Accuray. In 2025, T2S reported revenues of MAD 1.76 billion, with recurring activities contributing 46% of total sales.
Future Growth and Expansion Plans
The capital raised from the IPO will be pivotal in financing T2S’s ambitious expansion strategy, which includes investments in innovation, local manufacturing capabilities, acquisitions, and broadening its presence across francophone Africa. The company aims to achieve a revenue target of MAD 2.14 billion in 2026 and seeks to more than double its annual revenue to MAD 4.17 billion by 2030. Helios Investment Partners, which invested in T2S in 2021, maintains a significant stake of 42% in the company following this public offering.
T2S’s successful market debut is a strong indicator of revitalized interest in Morocco's capital markets, showcasing a growing appetite among investors for healthcare and technology sectors. The overwhelming oversubscription of the IPO reflects robust demand from both individual and institutional investors, which is particularly commendable given the current global climate for initial public offerings. This development not only reinforces Casablanca’s stature as a vibrant equity market in Africa but also enhances T2S’s capacity to access public capital, which will facilitate the expansion of its integrated healthcare platform and bolster recurring revenue streams. As demand for advanced medical equipment and diagnostic services continues to surge across the continent, T2S’s strategic approach could serve as a blueprint for other healthcare and technology enterprises contemplating public market entries as a viable path for sustainable growth.
As reported by dabafinance.com.
